Product
Low-Dose CICR-NAM
1 clinical trial
2 indications
Indication
ulcerative colitisIndication
UnspecifiedClinical trial
A Phase II/III, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) for Induction and Maintenance Therapy in Patients With Mild to Moderately Active Ulcerative ColitisStatus: Not yet recruiting, Estimated PCD: 2027-08-01